Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SADRA S JAZAYERI

Allopathic & Osteopathic Physicians Dermatology

NPI
1700893864
CMS profile
213624
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$16,209.85

173 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SADRA S JAZAYERI

NPI 1700893864 · CMS profile ID 213624

Allopathic & Osteopathic Physicians / Dermatology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700893864?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SADRA S JAZAYERI, NPI 1700893864, CMS profile ID 213624. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700893864?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). SADRA S JAZAYERI, NPI 1700893864, CMS profile ID 213624. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700893864?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
SADRA S JAZAYERI, NPI 1700893864, CMS profile ID 213624, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1700893864?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

173 matching records · $16,209.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 173 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 173.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SUN PHARMACEUTICAL INDUSTRIES INC. $13.1505/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851925681 CMS
Janssen Biotech, Inc. $1,150.0005/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788590437 CMS
UCB, Inc. $5.8905/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807376425 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $18.3405/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849565805 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $18.1405/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851925689 CMS
LEO Pharma Inc. $23.6005/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842209235 CMS
AbbVie Inc. $6.0205/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794957127 CMS
AbbVie Inc. $26.8305/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794957123 CMS
Lilly USA, LLC $19.0305/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818749443 CMS
UCB, Inc. $6.3605/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807367149 CMS
Genentech USA, Inc. $23.7905/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835972295 CMS
Novartis Pharmaceuticals Corporation $6.0705/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812732843 CMS
PFIZER INC. $21.0805/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832752519 CMS
UCB, Inc. $28.1805/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807310229 CMS
AbbVie Inc. $16.9905/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794957119 CMS
UCB, Inc. $6.8505/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807296073 CMS
Amgen Inc. $19.6004/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826426519 CMS
AbbVie Inc. $26.0704/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794957113 CMS
E.R. Squibb & Sons, L.L.C. $1,812.5004/26/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783592747 CMS
Novartis Pharmaceuticals Corporation $5.5304/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812732841 CMS
UCB, Inc. $6.1104/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807348893 CMS
Amgen Inc. $15.4904/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826426515 CMS
PFIZER INC. $19.5004/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832629495 CMS
Lilly USA, LLC $13.6704/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818678857 CMS
Amgen Inc. $20.9604/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826426511 CMS
Amgen Inc. $33.7404/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826426507 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $25.1104/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851925691 CMS
AbbVie Inc. $29.5404/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794957109 CMS
UCB, Inc. $7.6904/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807348741 CMS
Amgen Inc. $23.2804/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826426503 CMS
GENZYME CORPORATION $21.5904/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843567795 CMS
Novartis Pharmaceuticals Corporation $20.2503/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812732839 CMS
UCB, Inc. $7.7503/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807309769 CMS
AbbVie Inc. $23.9703/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794957105 CMS
LEO Pharma Inc. $9.6203/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842209223 CMS
Amgen Inc. $25.0603/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826426499 CMS
Genentech USA, Inc. $21.8503/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835972291 CMS
Janssen Biotech, Inc. $5.4303/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788590453 CMS
PFIZER INC. $19.9503/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832735731 CMS
Almirall LLC $5.8903/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 860933471 CMS
Novartis Pharmaceuticals Corporation $21.9203/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812732837 CMS
AbbVie Inc. $16.2503/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794957101 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $19.8903/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849565807 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $24.2903/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851925685 CMS
LEO Pharma Inc. $20.7103/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842209215 CMS
Amgen Inc. $24.0303/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826426495 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $13.0603/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851925679 CMS
Almirall LLC $800.0002/25/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819687579 CMS
Novartis Pharmaceuticals Corporation $18.5302/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812732835 CMS
GENZYME CORPORATION $17.0502/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843567761 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $33,942.80 211
PY2020 $14,641.44 139
PY2021 $16,209.85 173
PY2022 $19,722.85 164
PY2023 $11,901.25 192
PY2024 $16,194.69 170
PY2025 $2,422.78 123

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,717.58 1
PY2025 Principal investigator $317,740.45 68
PY2024 Principal investigator $429,373.93 198
PY2023 Principal investigator $464,147.46 110
PY2022 Recipient $3,385.00 1
PY2022 Principal investigator $333,154.30 59
PY2021 Recipient $10,606.24 2
PY2021 Principal investigator $554,824.57 44
PY2020 Recipient $1,371.00 2
PY2020 Principal investigator $494,097.81 63
PY2019 Recipient $7,126.00 2
PY2019 Principal investigator $2,465,362.55 71

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

69 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,529.40 12/31/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTER
A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult and adolescent subjects with severe alopecia areata No dispute reported 06/30/2026 1202532829
Principal investigator 1 ABBVIE INC. $665.04 12/31/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTER
A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis No dispute reported 06/30/2026 1202533019
Principal investigator 1 ABBVIE INC. $3,537.36 12/31/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTER
A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy, Safety, and Tolerability of Upadacitinib in Adult and Adolescent Subjects with Non-Segmental Vitiligo Who Are Eligible for Systemic Therapy No dispute reported 06/30/2026 1202533021
Principal investigator 1 ABBVIE INC. $5,746.20 12/04/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202527492
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,521.88 12/04/2025 Non-covered Recipient Entity
Alliance Dermatology & MOHS Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430668
Principal investigator 1 Biofrontera Inc. $22,806.40 11/27/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907732
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,343.75 11/19/2025 Non-covered Recipient Entity
Alliance Dermatology & MOHS Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430666
Principal investigator 1 ABBVIE INC. $3,998.39 11/13/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202524177
Principal investigator 1 ABBVIE INC. $3,335.00 11/04/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202520639
Principal investigator 1 ABBVIE INC. $462.60 11/04/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202520641
Principal investigator 1 ABBVIE INC. $3,745.20 11/04/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202520761
Principal investigator 1 ABBVIE INC. $8,447.80 11/04/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202520763
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Alliance Dermatology And Mohs Center
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235999125
Principal investigator 1 Janssen Research & Development, LLC $1,257.00 10/27/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTE
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175349785
Principal investigator 1 Janssen Research & Development, LLC $3,556.20 10/23/2025 Non-covered Recipient Entity
Allnce Derm and Mohs Center-Phoenix Ofc
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175164925
Principal investigator 1 Eli Lilly and Company $29,448.00 10/14/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTER PC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187876261
Principal investigator 1 ABBVIE INC. $4,561.40 10/09/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202514541
Principal investigator 1 ABBVIE INC. $526.00 10/09/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (Level Up) No dispute reported 06/30/2026 1202514543
Principal investigator 1 ABBVIE INC. $2,115.00 10/09/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202514725
Recipient Eli Lilly and Company $2,717.58 10/08/2025 Covered Recipient Physician A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE ATOPIC DERMATITIS AND HIGH ITCH BURDEN No dispute reported 06/30/2026 1187871433
Principal investigator 1 Novartis Pharmaceuticals Corporation $205.70 10/08/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTER
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190308256
Principal investigator 1 Biofrontera Inc. $7,000.00 09/30/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907621
Principal investigator 1 Janssen Research & Development, LLC $1,920.00 09/01/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTE R PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175349778
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $5,100.31 08/20/2025 Non-covered Recipient Entity
Alliance Dermatology & MOHS Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430664
Principal investigator 1 ABBVIE INC. $5,458.60 08/13/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202504447
Principal investigator 1 Eli Lilly and Company $4,694.94 08/08/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTER PC
A PHASE 4, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH ATOPIC DERMATITIS WITH LIMITED BODY SURFACE AREA INVOLVEMENT AND HIGH ITCH BURDEN (ADSOLVE) No dispute reported 06/30/2026 1187872543
Principal investigator 1 ABBVIE INC. $1,536.80 08/05/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202501924
Principal investigator 1 Janssen Research & Development, LLC $4,193.90 07/31/2025 Non-covered Recipient Entity
Allnce Derm and Mohs Center-Phoenix Ofc
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175165410
Principal investigator 1 ABBVIE INC. $1,333.50 07/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202495223
Principal investigator 1 ABBVIE INC. $1,354.60 07/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202495225
Principal investigator 1 ABBVIE INC. $3,163.20 07/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495227
Principal investigator 1 ABBVIE INC. $3,091.40 07/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202495229
Principal investigator 1 ABBVIE INC. $1,676.40 07/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202495231
Principal investigator 1 Biofrontera Inc. $9.86 06/25/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
STUDY TO EVALUATE THE SAFETY AND EFFICACY OFBF-200ALA(AMELUZ) AND BF-RHODOLED IN THE TREATMENT OF SUPERFICIALBASAL CELL CARCINOMA(SBCC) WITH PHOTODYNAMIC THERAPY (PDT). No dispute reported 06/30/2026 1208907518
Principal investigator 1 Biofrontera Inc. $1,500.00 06/13/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A NON-RANODMIZED, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF BF-200 ALA (AMELUZ) AND BF-RHODOLED XL IN THE EXPANDED FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS ON THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY (PDT) No dispute reported 06/30/2026 1208907458
Principal investigator 1 Eli Lilly and Company $9,557.00 06/11/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTER PC
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187875189
Principal investigator 1 ABBVIE INC. $4,231.80 06/03/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202487471
Principal investigator 1 ABBVIE INC. $1,869.80 06/03/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202487473
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $3,930.63 05/29/2025 Non-covered Recipient Entity
Alliance Dermatology & MOHS Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430662
Principal investigator 1 Janssen Research & Development, LLC $2,328.00 05/26/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTE R PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175349751
Principal investigator 1 Janssen Research & Development, LLC $5,334.30 05/08/2025 Non-covered Recipient Entity
Allnce Derm and Mohs Center-Phoenix Ofc
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175166639
Principal investigator 1 ABBVIE INC. $1,465.20 05/07/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202483167
Principal investigator 1 ABBVIE INC. $1,932.30 05/07/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202483169
Principal investigator 1 ABBVIE INC. $1,973.20 05/06/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202481695
Principal investigator 1 ABBVIE INC. $2,623.00 05/06/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202481697
Principal investigator 1 ABBVIE INC. $7,169.40 04/16/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202476838
Principal investigator 1 ABBVIE INC. $6,404.80 04/03/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata (Up-AA) No dispute reported 06/30/2026 1202468864
Principal investigator 1 ABBVIE INC. $1,465.20 04/03/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202474254
Principal investigator 1 ABBVIE INC. $4,561.40 04/03/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202474258
Principal investigator 1 ABBVIE INC. $2,534.20 04/03/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202474263
Principal investigator 1 Janssen Research & Development, LLC $447.00 04/03/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTE R PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175349774
Principal investigator 1 Janssen Research & Development, LLC $1,460.00 03/24/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTE R PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175349759
Principal investigator 1 ABBVIE INC. $311.27 03/17/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202463963
Principal investigator 1 ABBVIE INC. $5,374.20 03/07/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202460343
Principal investigator 1 ABBVIE INC. $6,314.40 03/06/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202457423
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $4,601.56 03/03/2025 Non-covered Recipient Entity
Alliance Dermatology & MOHS Center
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata No dispute reported 06/30/2026 1246430660
Principal investigator 1 Janssen Research & Development, LLC $45.00 02/25/2025 Non-covered Recipient Entity
Allnce Derm and Mohs Center-Phoenix Ofc
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175166647
Principal investigator 1 Biofrontera Inc. $26.65 02/20/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907331
Principal investigator 1 Biofrontera Inc. $1.36 02/13/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907283
Principal investigator 1 ABBVIE INC. $2,376.80 02/06/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202447198
Principal investigator 1 ABBVIE INC. $2,738.60 02/06/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202447202
Principal investigator 1 ABBVIE INC. $1,354.60 02/05/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M23-702 - Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis No dispute reported 06/30/2026 1202444199
Principal investigator 1 Janssen Research & Development, LLC $3,512.00 01/27/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY AND MOHS CENTE R PC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175349766
Principal investigator 1 Janssen Research & Development, LLC $6,401.67 01/23/2025 Non-covered Recipient Entity
Allnce Derm and Mohs Center-Phoenix Ofc
A Multicenter, Open Registry of Patients With Plaque Psoriasis Who Are Candidates for Systemic Therapy Including Biologics No dispute reported 06/30/2026 1175166632
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $34,422.74 01/17/2025 Non-covered Recipient Entity
Alliance Dermatology And Mohs Center
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235999127
Principal investigator 1 Biofrontera Inc. $22,396.45 01/15/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF BF-200 ALA (AMELUZ) IN THE FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS (AK) ON THE EXTREMITIES AND NECK/TRUNK WITH PHOTODYNAMIC THERAPY (PDT) USING A RHODOLED LAMP No dispute reported 06/30/2026 1208907257
Principal investigator 1 ABBVIE INC. $1,900.60 01/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M19-044 - A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo (Viti-Up) No dispute reported 06/30/2026 1202433780
Principal investigator 1 ABBVIE INC. $1,139.00 01/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202433785
Principal investigator 1 Amgen Inc. $18,633.20 01/02/2025 Non-covered Recipient Entity
ALLIANCE DERMATOLOGY & MOHS CENTER
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246639003